Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NDA for Lurasidone for Schizophrenia Accepted by FDA: DSP
March 29, 2010
- Febuxostat Launched in Europe: Teijin
March 29, 2010
- NDA for Bendamustine Submitted in Taiwan: SymBio
March 29, 2010
- Quintiles Relocates Its Global Central Lab in Japan to Tokyo
March 29, 2010
- Dry AMD Treatment ACU-4429 Receives Fast-Track Designation from the FDA: Otsuka, Acucela
March 29, 2010
- Symbicort Ranked No. 1 on GP Market
March 22, 2010
- WG to Be Created to Increase Self-Sufficiency Rate for Blood Products
March 22, 2010
- Booz & Company Proposes New Contract Manufacturing Business Model
March 22, 2010
- JMA Strongly Opposed to Promotion of “Integrated Medicine”
March 22, 2010
- Ajinomoto Pharm. to Set Out in April
March 22, 2010
- Vaccine-Related Societies to Create Consortium to Deal with Korosho
March 22, 2010
- Korosho Completes Hearings of Dispensing Pharmacy Chain Operators
March 22, 2010
- Requirements for High-Risk Drug Premium Explained by Korosho
March 22, 2010
- New Premium for Development of New Drugs “Poison Bait”
March 22, 2010
- Shionogi to Comarket Quick Chaser Flu A, B with Mizuho Medy
March 22, 2010
- Santen Files NDA for Higher-Concentration Levofloxacin
March 22, 2010
- Leading Generics-Only Companies'Foothold Undermined by Entry of Big Pharmas
March 22, 2010
- CDFS's Dept. on Drugs to Review Rozerem, DE-089, Soliris
March 22, 2010
- ¥105 Bil. Sales of Aricept to Be Lost in 3 Years Following Patent Expiration in the US
March 22, 2010
- 5-Day Dosing Regimen Approved for Dacogen in the US: Eisai
March 22, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…